COVID-19, severe asthma, and biologics

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of allergy, asthma, & immunology asthma, & immunology, 2020-09, Vol.125 (3), p.357-359.e1
Hauptverfasser:	García-Moguel, Ismael, Díaz Campos, Rocío, Alonso Charterina, Sergio, Fernández Rodríguez, Consuelo, Fernández Crespo, Jesús
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetates - therapeutic use Adrenergic beta-2 Receptor Antagonists - therapeutic use Amoxicillin-Potassium Clavulanate Combination - therapeutic use Anti-Asthmatic Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Asthma - complications Asthma - drug therapy Asthma - immunology Asthma - virology Azithromycin - therapeutic use Betacoronavirus - immunology Betacoronavirus - pathogenicity Budesonide - therapeutic use Convalescence Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - virology COVID-19 Eosinophils - drug effects Eosinophils - immunology Eosinophils - virology Female Humans Hydroxychloroquine - therapeutic use Ipratropium - therapeutic use Male Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - virology Quinolines - therapeutic use SARS-CoV-2 Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!